MX2014016121A - Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular. - Google Patents

Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.

Info

Publication number
MX2014016121A
MX2014016121A MX2014016121A MX2014016121A MX2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A
Authority
MX
Mexico
Prior art keywords
vascular endothelial
endothelial function
agent
salt
preventing deterioration
Prior art date
Application number
MX2014016121A
Other languages
English (en)
Inventor
Masahiko Morita
Miho Komatsu
Takahiro Hara
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of MX2014016121A publication Critical patent/MX2014016121A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un agente de mejora de producción de NO, que comprende citrulina o una sal de la misma y serina o una sal de la misma como ingredientes activos; un agente para prevenir el deterioro de una función endotelial vascular o para mejorar la función endotelial vascular, que comprende citrulina o una sal de la misma y serina o una sal de la misma como ingredientes activos; y un agente profiláctico o benéfico para las afecciones asociadas con el deterioro de una función endotelial vascular, que comprende citrulina o una sal de la misma y serina o una sal de la misma como ingredientes activos.
MX2014016121A 2012-06-29 2013-06-28 Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular. MX2014016121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012146572 2012-06-29
PCT/JP2013/067767 WO2014003154A1 (ja) 2012-06-29 2013-06-28 血管内皮機能低下の予防または改善剤

Publications (1)

Publication Number Publication Date
MX2014016121A true MX2014016121A (es) 2015-09-21

Family

ID=49783288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014016121A MX2014016121A (es) 2012-06-29 2013-06-28 Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.

Country Status (5)

Country Link
US (1) US9833426B2 (es)
JP (1) JP6193229B2 (es)
CA (1) CA2877953A1 (es)
MX (1) MX2014016121A (es)
WO (1) WO2014003154A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5888574B1 (ja) * 2015-07-02 2016-03-22 株式会社東洋新薬 血流改善剤
JP7123977B2 (ja) * 2017-05-31 2022-08-23 協和発酵バイオ株式会社 筋量を増大させるためのシトルリンおよびグルタチオンの使用
IT201700089011A1 (it) * 2017-08-02 2019-02-02 Kolinpharma S P A Composizione per il trattamento e la prevenzione di disturbi della sfera sessuale maschile.
US20210283082A1 (en) * 2018-06-07 2021-09-16 National University Corporation Kanazawa University Pharmaceutical composition for prevention or treatment of kidney damage
JP7364166B2 (ja) * 2018-06-07 2023-10-18 国立大学法人金沢大学 腎障害の予防又は治療用の医薬組成物
CA3123531A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic combinations of nicotinamide and nitrate enriched amaranthus extract for use in treating vascular endothelial disorders
CA3123524C (en) 2019-01-02 2024-01-23 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
JP6838752B2 (ja) * 2019-08-30 2021-03-03 株式会社東洋新薬 血流改善組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3914585B2 (ja) * 1995-10-19 2007-05-16 イーエヌ大塚製薬株式会社 マクロファージ一酸化窒素産生亢進剤
JP3843298B2 (ja) 2001-02-05 2006-11-08 国立大学法人 奈良先端科学技術大学院大学 シトルリンを含有する活性酸素消去剤
JP2002316929A (ja) * 2001-04-18 2002-10-31 Japan Science & Technology Corp L−セリン又はグリシンからなる抗アポトーシス剤
JP2006282648A (ja) * 2005-03-31 2006-10-19 Sunstar Inc 美容食品用組成物
JP5697835B2 (ja) * 2005-12-05 2015-04-08 協和発酵バイオ株式会社 皮膚の乾燥予防または改善用経口剤
JP2008222632A (ja) 2007-03-13 2008-09-25 Kyowa Hakko Kogyo Co Ltd 関節炎改善剤
JP2008273910A (ja) * 2007-05-07 2008-11-13 Kyowa Hakko Kogyo Co Ltd 化粧料または皮膚外用剤

Also Published As

Publication number Publication date
JP6193229B2 (ja) 2017-09-06
US20150141514A1 (en) 2015-05-21
JPWO2014003154A1 (ja) 2016-06-02
US9833426B2 (en) 2017-12-05
WO2014003154A1 (ja) 2014-01-03
CA2877953A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
MX2014016121A (es) Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.
EP3441468A3 (en) Delivery methods and compositions for nuclease-mediated genome engineering
MX371497B (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
MX354137B (es) Composiciones topicas de minociclina y metodos de uso de la misma.
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX338015B (es) Composiciones que comprenden un componente de estabilidad de la vida util.
MX2015000995A (es) Formulaciones desinfectantes topicas y uso de las mismas.
WO2012006538A8 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
PH12015500900B1 (en) A stabilized pemetrexed formulation
WO2013173789A3 (en) Antisense oligonucleotide compositions
AU337887S (en) Allsaw
AU339376S (en) Sterilizing case
AU341603S (en) Washer
MX2013009252A (es) Composiciones y procesos relacionados con los mismos plaguicidas.
AR088099A1 (es) Composicion anticaspa
CA144465S (en) Landscape edger
MX2015003711A (es) Metodos y composiciones para extender la vida útil en déposito de productos de plantas.
CA144467S (en) Landscape edger
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.
AU337888S (en) Allsaw
CA145236S (en) Pitcher
CA145238S (en) Cup for tea
WO2013095994A3 (en) Transparent aqueous fragrance microemulsions
潘基文 et al. The Secretary-General’s Message on World Environment Day